BioCentury | May 13, 2020
Product Development

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

Autoimmune, metabolic diseases added to Skyhawk-Merck deal  Skyhawk Therapeutics Inc. expanded a collaboration with Merck & Co. Inc. (NYSE:MRK) to discover and develop small molecules that modulate RNA splicing for autoimmune and metabolic diseases; the...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BC Extra | Nov 15, 2019
Company News

BeiGene enters U.S. market with first approval for in-house pipeline

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...
BC Innovations | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
BC Extra | Apr 26, 2019
Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

The Department of Justice said Thursday that Amgen and Astellas have agreed to pay $124.8 million combined to settle allegations of kickbacks to charitable patient assistance programs. Astellas Pharma Inc. (Tokyo:4503) will pay $100 million...
BC Week In Review | Oct 5, 2018
Clinical News

FDA approves once-weekly dosing of Amgen's Kyprolis

Amgen Inc. (NASDAQ:AMGN) said FDA approved an sNDA for a once-weekly 70 mg/m 2 dosing option for Kyprolis carfilzomib in combination with dexamethasone to treat relapsed or refractory multiple myeloma. The selective proteasome inhibitor is...
BC Extra | Jul 26, 2018
Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
BC Week In Review | May 4, 2018
Clinical News

Karyopharm planning selinexor submissions in MM

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reported that selinexor (KPT-330) met the primary endpoint of improving overall response rate (ORR) in the Phase IIb STORM trial to treat penta-refractory multiple myeloma. Based on the data, the company...
Items per page:
1 - 10 of 265